Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05715255 · ClinicalTrials.gov registry record · NA

Adaptive Symptom Self-Management Immunotherapy Study

A NA study of Breast Cancer and Lung Cancer, sponsored by University of Arizona.

Recruiting
Registry status
NA
Development phase
400
Enrollment target
3
Study locations

NCT05715255: Recruiting NA study of Breast Cancer and Lung Cancer, sponsored by University of Arizona.

NCT05715255 is a NA study of Breast Cancer and Lung Cancer that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 400 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05715255, a NA study of Breast Cancer and Lung Cancer, is actively recruiting participants, sponsored by University of Arizona.

RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
3
Study locations

Study Summary

The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.

Primary Outcome

Patient Reported Outcomes Measurement Information System (PROMIS) has been developed using sophisticated measurement techniques, tested with over 21,000 individuals, calibrated to produce t-scores based on the general population and are available in either English or Spanish. The available short forms have evidence of good reliability and validity. PROMIS-short form 8 for depression and anxiety will be administered at baseline and 17-week telephone interviews to provide greater detail and precis

Interventions

  • BEHAVIORAL Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)
  • BEHAVIORAL Active control comparator

Study Locations (3)

Arizona

  • Valleywise Health Medical Center - Phoenix
  • University of Arizona Cancer Center - Tucson

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2023-05-08
Est. Completion 2027-04-30
Phase NA
University of Arizona

349 total trials

What NCT05715255 shows while recruiting

NCT05715255 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower).

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C) is the first listed.

NCT05715255 reports a single indexed study location in Arizona, Michigan.

Frequently Asked Questions

What is clinical trial NCT05715255 about?

NCT05715255 is a clinical study titled "Adaptive Symptom Self-Management Immunotherapy Study". The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or se...

What is the current status of trial NCT05715255?

This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2023-05-08. Estimated completion is 2027-04-30.

What conditions does trial NCT05715255 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Colon Cancer, Skin Cancer, Rectum Cancer.

What interventions are being tested in trial NCT05715255?

The interventions under investigation include: Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C) (BEHAVIORAL), Active control comparator (BEHAVIORAL).

Who is sponsoring clinical trial NCT05715255?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05715255 being conducted?

This trial has 3 study locations across Arizona, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05715255's enrollment target sits among peer trials

400 233rd of 1224 higher than 981 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02285582 · 400 participants

    International Rare Histiocytic Disorders Registry (IRHDR)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05715255, the US trial registry maintained by the National Library of Medicine. NCT05715255 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.